Advertisement

Topics

Vectura racks up huge loss following failure of severe asthma inhaler in late-stage study

05:16 EDT 26 Mar 2019 | Proactive Investors

The drugmaker decided to write down the value of its VR745 asthma treatment to zero following its late-stage trial failure back in November

Original Article: Vectura racks up huge loss following failure of severe asthma inhaler in late-stage study

NEXT ARTICLE

More From BioPortfolio on "Vectura racks up huge loss following failure of severe asthma inhaler in late-stage study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...